Susan O'Brien, MD | Authors

BTK Inhibitors for the Treatment of Relapsed CLL

January 20, 2023

Seema Ali Bhat, MD, explains the SEQUOIA trial and the BTK inhibitor zanubrutinib for the frontline treatment of CLL, and Alexey Danilov, MD, PhD, describes the ASCEND trial that led to the approval of acalabrutinib for relapsed CLL.